The global bone marrow transplant market size is calculated at USD 11.24 billion in 2025 and is expected to reach around USD 16.76 billion by 2034, growing at a CAGR of 4.54% for the forecasted period.
Ottawa, Nov. 03, 2025 (GLOBE NEWSWIRE) — The global bone marrow transplant market size was valued at USD 10.75 billion in 2024 and is predicted to hit around USD 16.76 billion by 2034, rising at a 4.54% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
This market is rising because of the growing prevalence of hematologic disorders and improved technological capabilities in transplant procedures.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5520
Key Takeaways:
- North America dominated the global bone marrow transplant market in 2024.
- Asia-Pacific is expected to grow significantly during the forecast period.
- By transplant type, the autologous transplant segment dominated the market in 2024.
- By transplant type, the allogenic transplant segment is estimated to grow at a notable CAGR during the forecast period.
- By treatment type, the leukemia segment dominated the global bone marrow transplant market in 2024.
- By treatment type, the sickle cell anemia segment is predicted to grow significantly during the forecast period.
- By end-user, the hospital segment dominated the market in 2024.
- By end-user, the multi-specialty clinics segment is anticipated to show lucrative growth during the forecast period.
Market Overview:
What Are the Expectations for the Expansion of the Bone Marrow Transplant Market?
The bone marrow transplant market is focused on healthcare in which patients receive replacement of their damaged or diseased marrow with healthy stem cells, and is regularly used in the treatment of blood cancers, immune deficiency and genetic disorders. The bone marrow transplant market is increasingly developing in matured and emerging healthcare markets driven by innovations in transplantation techniques, improved donor registries and treatment modalities for transplant potentially bridging access to treatment.
Confidence has grown in transplantation as a curative or life-prolonging treatment as several dedicated centers, clinic protocols and patient outcomes have followed through the transplants. The market is now rapidly advancing globally with increased awareness and access to infrastructure and market demand.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Major Growth Drivers:
What Are the Contributing Factors to The Growth of The Bone Marrow Transplant Market?
A leading market growth factor for bone marrow transplantation is the increasing incidence of blood cancers and diseases. The demand for curative treatment strategies such as bone marrow transplant has increased significantly, due to the growing prevalence of conditions such as leukemia, lymphoma, multiple myeloma and aplastic anemia around the world.
Additionally, continuously improving donor matching technology, managing clinical complications related to graft-versus-host disease (GVHD), and widening access to cord blood and haplo-identical transplantation are also increasing the eligible patient population and increasing treatment utilization.
The growing investment in healthcare services from governments and private industry, the increasing number of registries, and public education and awareness are also creating opportunities for more centers to deliver these highly specialized procedures, further accelerating market growth.
Key Drifts:
What Are The Main Trends That Are Affecting The Bone Marrow Transplant Market?
A key trend within the bone marrow transplant space has been a movement away from traditional full-match donor transplants toward more flexible donor paradigms, like haplo-identical and cord blood transplantation, that are lessening wait times and increasing eligibility. On the heels of this, advanced technologies such as AI-powered donor-matching analytics, enhanced cellular processing and cryopreservation methods, and individualized conditioning regimens are being leveraged to improve outcomes and reduce complications.
In addition, outpatient or reduced-hospital stay transplant protocols are garnering support in select markets, decreasing cost burden and enhancing patient experience. Collectively, such structural shifts within transplant practice are also widening the acceptance of and accessibility to bone marrow transplant procedures on a global basis.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Significant Challenge:
What Is The Main Challenges in the Bone Marrow Transplant Market?
A significant difficulty that the bone marrow transplant market faces is ongoing transplant-related complications, particularly graft-versus-host disease (GVHD) in allogeneic transplants, which contributes to morbidity, increases hospital stays, and increases overall cost burden. Furthermore, the procedural costs and highly specialised infrastructure and multidisciplinary post-transplant care, discourages broader access in many low-income and middle-income regions.
The lack of donors, particularly for ethnically diverse populations, and the difficulties associated with locating well-matched donors hinder broader uptake. All of these factors combined impede market growth in various geographies, even when there is a clear demand for transplants.
Regional Analysis:
The North America market is firmly established and benefitted from a strong healthcare infrastructure, established stem cell donor registries and a high burden of hematologic disease that warrants strong demand for transplants. The region has strong regulatory support, and has received considerable research investment, and it remains the greatest contributor to global market value.
The Asia-Pacific market, driven by increasing disease prevalence, increased medical infrastructure, low-cost options for services, and increasing awareness of BMT as a transplant option, is the fastest growing market. Additionally, new transplant centres are being established in emerging markets such as India and China, with sizeable procedure volumes.
Segmental Insights:
By Transplant Type:
In 2024 the autologous transplant segment retained the dominant share of the transplant type market, mirroring its much broader use and lower complication rates. The fact that autologous transplants use the patient’s own stem cells harvested and reinfused after chemotherapy, avoids complications including graph versus host disease, and the risks of immunologic rejection, is a benefit for both patients and strong acceptance amongst clinicians.
Autologous transplant compatibility leads to shorter recovery times and results which do not depend on donors. High dose chemotherapy used to treat malignancies, such as multiple myeloma and lymphoma, will most situations result in autologous transplantation. This will provide stable and growing demand for such procedures.
In the forecast period, the allogeneic transplant segment is forecasted to see strong growth from biopharmaceutical advancements in donor-matched transplant and haplo-identical transplant technologies. Allogeneic procedures, which use donor stem cells, have the advantage of a potentially graft versus tumour effect and this is attractive when treating hematologic malignancies of high-risk and genetic disorders. As the expanded potential for donor registries, cord blood banking, and the better utilization of haplo-matched donors become more common, access to donor transplants is being improved. The decrease and better management of complication such as graft-versus-host disease are more carefully balanced with the conditioning regimens improving the clinical outcome, and this may drive overall adoption.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
By Treatment Type:
The leukemia indication segment topped the market in 2024, reflecting the high incidence of leukemia around the world, and in many cases the established role of bone marrow transplantation as a curative therapy. In acute myeloid leukemia and acute lymphoblastic leukemia, transplant remains one of the most effective therapies for eligible patients, increasing demand for transplant services. There is an associated urgency for transplant in the context of relapse and refractory leukemia that also contributes to the segment’s strength. Many treatment protocols for leukemia prioritize transplant early in the disease course, which creates ongoing procedural volumes.
During the forecast period the sickle cell anaemia indication is anticipated to see significant growth within the bone marrow transplant market, as improved transplant protocols and donor expansion contribute to the curative option. Transplantation for sickle cell disease has traditionally been limited due to issues with donor availability, risk, and cost. However, the transplant treatment of sickle cell disease is becoming increasingly feasible due to ongoing advances, including half-matched donors and reduced-intensity conditioning. Public and transplant center awareness has grown and perspectives are shifting to non-malignant indications which both expand the eligible patient population and the sickle cell anaemia market potential.
By End-users:
A key end-user of bone marrow transplantation is hospitals in the year 2024. Hospitals have the most infrastructure in place, a multidisciplinary team, and logistics to manage the pre- and post-ongoing care and protocols. Most large hospital centres have transplant teams which in most cases would include transplant units, stem-cell processing facilities, intensive care support and supportive environments with infection-control measures in place. This makes hospitals a default Centre to deliver care. Furthermore, most hospitals contain oncology and hematology and transplant services all under one roof, which will eliminate complexity in moving patients through the patient pathway, especially for complicated multi-stage transplant procedures.
Over time, hospitals will still maintain their end-user market share throughout the forecast period, but multi-specialty clinics will also get their foothold as an attractive end-user in the bone marrow transplant market, with promising growth projections for the future. Multi-specialty clinics can provide care in settings with multiple specialties to provide, hematology, oncology, transplant coordination and follow up care. In some markets, multi-specialty clinics could provide care with less barriers to access as compared to large hospital systems. As outpatient transplantation protocols evolve and patient pathways are streamlined to simple care, multi-specialty clinics will be able to use lower overhead costs and provide medical procedures in a more convenient way for the patient.
Recent Developments:
- On October 17, 2025, All India Institute of Medical Sciences Nagpur (AIIMS Nagpur) signed an MoU with the Bal Ayush Foundation and the Thalassemia and Sickle Cell Society of India to strengthen its bone marrow transplant (BMT) services by constructing two additional state-of-the-art BMT rooms, increasing facility capacity and enabling more commercial-scale transplant access in central India. This expansion of infrastructure in a key emerging market underscores the global growth potential of the transplant market.
Browse More Insights of Towards Healthcare:
The global insulin analog market is valued at USD 16.99 billion in 2024, expected to rise to USD 17.68 billion in 2025, and further reach approximately USD 25.29 billion by 2034, expanding at a CAGR of 4.06% from 2025 to 2034.
The global dental bite guard market is projected at USD 1.29 billion in 2024, increasing to USD 1.38 billion in 2025, and anticipated to hit around USD 2.52 billion by 2034, growing at a CAGR of 6.95% during the forecast period.
The global percutaneous nephrolithotomy (PCNL) system market was valued at USD 1.34 billion in 2024, reached USD 1.44 billion in 2025, and is forecast to attain approximately USD 2.7 billion by 2034, witnessing a CAGR of 7.25% between 2025 and 2034.
The medical disposable positioning products market was valued at USD 1.06 billion in 2024 and is projected to grow to USD 1.13 billion in 2025, reaching nearly USD 2.04 billion by 2034, expanding at a CAGR of 6.75% over the forecast period.
The global MRI 3T cochlear implant market is estimated at USD 821 million in 2024, rising to USD 902.78 million in 2025, and expected to reach about USD 2.10 billion by 2034, registering a strong CAGR of 9.96% between 2025 and 2034.
The global dental RCM services market stood at USD 711 million in 2024, grew to USD 748.3 million in 2025, and is projected to reach nearly USD 1.19 billion by 2034, advancing at a CAGR of 5.25% from 2025 to 2034.
The global cell culture microcarriers market is valued at USD 3.18 billion in 2024, expected to grow to USD 3.45 billion in 2025, and projected to reach approximately USD 7.2 billion by 2034, expanding at a CAGR of 8.54% over the forecast timeline.
The antipyretic and analgesic drugs market is valued at USD 47.47 billion in 2024, expected to rise to USD 49.89 billion in 2025, and anticipated to reach around USD 77.99 billion by 2034, recording a CAGR of 5.09% from 2025 to 2034.
The global ultra-high-end CT scanners market is estimated at USD 5.89 billion in 2024, rising to USD 6.25 billion in 2025, and forecast to reach nearly USD 10.69 billion by 2034, growing at a CAGR of 6.16% between 2025 and 2034.
The global outpatient blood pressure monitoring equipment market is valued at USD 1.27 billion in 2024, projected to increase to USD 1.38 billion in 2025, and expected to reach around USD 2.89 billion by 2034, expanding at a CAGR of 8.56% from 2025 to 2034.
Key Players in Bone Marrow Transplant Market:
| Company | Core Offering(s) | Recent Breakthrough / Focus Area |
| Novartis AG | Pharmaceuticals and cell/gene therapies | Advancing CAR-T cell therapies and regenerative treatments relevant to hematologic cancers and bone marrow transplants. |
| Bristol Myers Squibb | Biopharmaceuticals focused on oncology, hematology, and immunology | Strengthened cell therapy portfolio with CAR-T therapies (Abecma, Breyanzi) used in post-transplant relapse management. |
| Abbott Laboratories | Diagnostics, medical devices, and healthcare solutions | Provides diagnostic tools for stem cell and transplant monitoring; developing advanced immune diagnostics relevant to bone marrow engraftment. |
| Eli Lilly and Company | Pharmaceuticals across oncology, immunology, and metabolic disorders | Exploring oncology and hematology research programs that support pre- and post-transplant cancer management. |
| American Type Culture Collection (ATCC) | Biological materials and cell lines for research | Supplies human and animal cell cultures, including hematopoietic and stem cell models used in bone marrow transplant research. |
| Magenta Therapeutics | Regenerative medicine and stem cell transplantation | Focused on improving bone marrow transplant conditioning and stem cell mobilization through targeted biologics. |
| Hemacare Corporation | Human-derived biological products and cell therapy materials | Provides hematopoietic stem and immune cells for transplant and cell therapy manufacturing. |
| Bayer AG | Pharmaceuticals with expertise in oncology and hematology | Expanding hematologic cancer pipeline and exploring cell-based therapies that align with transplant-related indications. |
| ReeLabs Pvt. Ltd. | Stem cell banking and regenerative medicine | Specializes in stem cell collection, processing, and storage for use in bone marrow and regenerative treatments. |
| FUJIFILM Cellular Dynamics | Induced pluripotent stem cell (iPSC) technology and cell manufacturing | Develops iPSC-derived hematopoietic cells for research and therapeutic applications, including bone marrow regeneration. |
| STEMCELL Technologies | Cell culture media and tools for stem cell and immunology research | Provides specialized products for hematopoietic stem cell culture, differentiation, and transplant research. |
Top Companies in the Bone Marrow Transplant Market
- Novartis AG
- Bristol Myers Squibb
- Abbott Laboratories
- Eli Lilly and Company
- American Type Culture Collection
- Magenta Therapeutics
- Hemacare Corporation
- Bayer AG
- ReeLabs Pvt. Ltd.,
- FUJIFILM Cellular Dynamics
- STEMCELL Technologies
Segments Covered in the Report
By Transplant Type
- Allogeneic Transplant
- Autologous Transplant
- Others
By Treatment Type
- Leukemia
- Lymphoma
- Sickle cell Anaemia
- Myeloma
- Thalassemia
- Myelodysplastic Syndrome
- Solid Tumours
- Myeloproliferative Disorders
By End-User
- Hospitals
- Multi-Specialty Clinics
- Ambulatory Surgical Centres
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5520
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at [email protected]
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.